03/16/2024
Popular Drug for Type 2 Diabetes May Reduce Glaucoma Risk
In a nationwide study, GLP-1RA treatment decreased the risk of development by 19%.
Additionally, those exposed to GLP-1RA for three years or longer had a 29% risk reduction. The study authors concluded that GLP-1RA may be beneficial as an adjunctive therapy to IOP-reducing eye drops in glaucoma management. Examples of medications that act as GLP-1RAs include Semaglutide (Ozempic, weekly), Exenatide (Byetta, twice daily), Liraglutide (Victoza, Saxenda, daily) and Lixisenatide (Adlyxin, daily).
Read more on the study: https://www.reviewofoptometry.com/article/popular-drug-for-type-2-diabetes-may-reduce-glaucoma-risk